Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.

Klausz, Katja; Pekar, Lukas; Boje, Ammelie Svea; Gehlert, Carina Lynn; Krohn, Steffen; Gupta, Tushar; Xiao, Yanping; Krah, Simon; Zaynagetdinov, Rinat; Lipinski, Britta; Toleikis, Lars; Poetzsch, Sven; Rabinovich, Brian; Peipp, Matthias; Zielonka, Stefan

Klausz, Katja; Pekar, Lukas; Boje, Ammelie Svea; Gehlert, Carina Lynn; Krohn, Steffen; Gupta, Tushar; Xiao, Yanping; Krah, Simon; Zaynagetdinov, Rinat; Lipinski, Britta; Toleikis, Lars; Poetzsch, Sven; Rabinovich, Brian; Peipp, Matthias; Zielonka, Stefan.

Affiliation

Klausz K; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein and Christian Albrechts University Kiel, Kiel, Germany.
Pekar L; Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
Boje AS; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein and Christian Albrechts University Kiel, Kiel, Germany.
Gehlert CL; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein and Christian Albrechts University Kiel, Kiel, Germany.
Krohn S; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein and Christian Albrechts University Kiel, Kiel, Germany.
Gupta T; Protein Engineering and Antibody Technologies, EMD Serono Research & Development Institute, Inc., Billerica, MA.
Xiao Y; Department of Oncology and Immuno-oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA.
Krah S; Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
Zaynagetdinov R; Department of Oncology and Immuno-oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA.
Lipinski B; Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
Toleikis L; Institute for Organic Chemistry and Biochemistry, Technical University of Darmstadt, Darmstadt, Germany; and.
Poetzsch S; Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany.
Rabinovich B; Strategic Innovation, Merck Healthcare KGaA, Darmstadt, Germany.
Peipp M; Department of Oncology and Immuno-oncology, EMD Serono Research & Development Institute, Inc., Billerica, MA.
Zielonka S; Division of Antibody-Based Immunotherapy, Department of Internal Medicine II, University Hospital Schleswig-Holstein and Christian Albrechts University Kiel, Kiel, Germany; matthias.peipp@uksh.de stefan.zielonka@merckgroup.com.

J Immunol ; 209(9): 1724-1735, 2022 11 01.

Article de En | MEDLINE | ID: mdl-36104113

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Cytokines / Récepteur-3 de déclenchement de cytotoxicité naturelle Limites: Humans Langue: En Journal: J Immunol Année: 2022 Type de document: Article Pays d'affiliation: Allemagne Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google